Management Team

 

At Nanomed, we provide fast and affordable tools for small molecule drug discovery. We have developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB)technology that detects molecular interactions. This technology employs a unique graphene biosensor to enable label-free, highly sensitive binding studies of small molecules to proteins. With a wide dynamic range, small sample requirements, and minimal signal contributions from common solvents and detergents, our technology complements existing technology and accelerates small molecule drug discovery.

As the world’s leading mass-manufacturer of next-generation graphene biosensors, our mission is to transform the healthcare industry with innovative new products that accelerate cutting-edge life science and drug discovery research.

Nanomed is a Cardea brand focused on providing fast and affordable tools for small molecule drug discovery. We have developed a breakthrough electrical assay based on proprietary optics-free Field Effect Biosensing (FEB) technology that detects molecular interactions. 

For more information, visit Cardea’s website.